Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Qualitest_Pharmaceuticals
Par Pharmaceutical AstraZeneca's_rights_to_certain_products Bristol-Myers_Squibb's_specialty_pharmaceuticals_business |
| gptkbp:CEO |
gptkb:Blaine_McPeak
|
| gptkbp:clinicalTrials |
ongoing studies
pain management therapies endocrine therapies urology treatments |
| gptkbp:employees |
approximately 2,000
|
| gptkbp:focus |
endocrinology
pain management urology |
| gptkbp:founded |
1997
|
| gptkbp:headquarters |
gptkb:Malvern,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Endo Pharmaceuticals
|
| gptkbp:legal_principle |
settlement agreements
opioid crisis |
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:partnerships |
gptkb:Sorrento_Therapeutics
academic institutions research organizations AcelRx Pharmaceuticals |
| gptkbp:philanthropy |
gptkb:Endo_Foundation
community health initiatives research grants patient advocacy support support for pain management education |
| gptkbp:products |
gptkb:Xyrem
Testosterone Opana ER Percocet Vasostrict |
| gptkbp:regulatoryCompliance |
FDA_approved_products
EMA_approved_products |
| gptkbp:research_focus |
rare diseases
chronic pain urological disorders |
| gptkbp:revenue |
$1.1 billion (2020)
|
| gptkbp:stockExchange |
ENDP
|
| gptkbp:subsidiary |
gptkb:Endo_Health_Solutions
|
| gptkbp:sustainability_initiatives |
community engagement
ethical sourcing practices environmental responsibility diversity and inclusion efforts employee well-being programs |
| gptkbp:type |
public company
|
| gptkbp:website |
www.endo.com
|